Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy

被引：0

作者：

R. H. Enting

P. Portegies

机构：

[1] Department of Neurology,

[2] Academic Medical Center H2-214,undefined

[3] Meibergdreef 9,undefined

[4] 1105 AZ,undefined

[5] Amsterdam,undefined

[6] The Netherlands e-mail: P.Portegies@amc.uva.nl Tel.: +31-20-5663842 Fax: +31-20-6971438,undefined

来源：

Journal of Neurology | 2000年 / 247卷

关键词：

Key words Progressive multifocal leukoencephalopathy; Anti-HIV agents; Cytarabine; HIV infection;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We assessed survival in AIDS-related progressive multifocal leukoencephalopathy (PML) and the effect of cytarabine and antiretroviral therapy in a retrospective analysis of a series of consecutive 35 patients with AIDS-related PML in an academic AIDS referral center over ¶15 years. Treatment regimens consisted of highly active antiretroviral treatment (HAART), intravenous cytarabine, or both. Median survival after diagnosis in the overall series was 88 days. Patients with low CD4 cell count tended to have shorter survival. Seven patients (20%) had prolonged survival (> 1 year). Cytarabine did not affect survival. Seven patients were treated with HAART, which did not significantly improve survival. We conclude that the prognosis of AIDS-related PML is still poor, with a median survival of ¶3 months.

引用

页码：134 / 138

页数：4

共 50 条

[41] Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects
Donati, KD
Bertagnolio, S
Tumbarello, M
Tacconelli, E
Cataldo, M
Longo, B
Cauda, R
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (03) : 357 - 360
[42] Cytomorphology of progressive multifocal leukoencephalopathy (PML): Review of sixteen cases occurring in HIV-positive patients
Yu, GH
Hidvegi, DF
Cajulis, RS
Brody, BA
Levy, RM
DIAGNOSTIC CYTOPATHOLOGY, 1996, 14 (01) : 4 - 9
[43] Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy
Calza, L
Manfredi, R
Colangeli, V
D'Antuono, A
Passarini, B
Chiodo, F
INTERNATIONAL JOURNAL OF STD & AIDS, 2003, 14 (05) : 356 - 359
[44] Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2
De Paoli P.
Zanussi S.
Caggiari L.
Bortolin M.T.
D'Andrea M.
Simonelli C.
Tirelli U.
Journal of Clinical Immunology, 1999, 19 (5) : 317 - 325
[45] Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response
Fardet, L.
Mary-Krause, M.
Heard, I.
Partisani, M.
Costagliola, D.
HIV MEDICINE, 2006, 7 (08) : 520 - 529
[46] Effect of Highly Active Antiretroviral Therapy on Fundus Images and Retinal Microvessel Diameter in HIV/AIDS Patients
Li, Qin
Chen, Dongqiong
Ye, Fang
Wang, Xiaoying
Yang, Shangsong
Wang, Li
Wen, Weibo
HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2023, 15 : 1 - 9
[47] Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998
Thiébaut, R
Dabis, F
Malvy, F
Jacqmin-Gadda, H
Mercié, P
Valentin, VD
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (03) : 261 - 265
[48] Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy
Riddler, S. A.
Li, X.
Chu, H.
Kingsley, L. A.
Dobs, A.
Evans, R.
Palella, F.
Visscher, B.
Chmiel, J. S.
Sharrett, A. R.
HIV MEDICINE, 2007, 8 (05) : 280 - 287
[49] Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy
Dray-Spira, R
Lert, F
AIDS, 2003, 17 (03) : 283 - 290
[50] Do Highly Active Antiretroviral Therapy Drugs in the Management of HIV Patients Influence Success of Dental Implants?
Sivakumar, Indumathi
Arunachalam, Sivakumar
Choudhary, Suchismita
Mahmoud-Buzayan, Muaiyed
Tawfiq, Omar
Sharan, Jitendra
AIDS REVIEWS, 2020, 22 (01) : 3 - 8

← 1 2 3 4 5 →